MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,157.08 -27.55 (-2.33%)
Official Closing Price Updated: 7:00 PM EDT, Sep 30, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
News headline image
VanEck Pharmaceutical ETF vs VanEck Biotech ETF: Which Fund Is Better for Drug Innovation Profits? ↗
PPH offers higher income and lower volatility, while BBH delivers stronger growth but with deeper drawdowns. 
Via The Motley Fool
Topics ETFs
News headline image
Eli Lilly's Momentum Looks Unstoppable -- but 1 Factor Could Change Everything ↗
The drugmaker has a lot riding on continued clinical progress. 
Via The Motley Fool
News headline image
3 Healthcare Stocks for 3 Stages of Life ↗
Healthcare stocks Eli Lilly, UnitedHealth Group, and Johnson & Johnson offer options for investors of different ages, combining growth potential, turnaround momentum, and reliable dividends. 
Via MarketBeat
Eli Lilly (NYSE:LLY) Combines Strong Growth With a Quality Technical Setup ↗
Via Chartmill
News headline image
3 Absurdly Cheap Growth Stocks to Buy Before the End of 2026 ↗
These stocks have been struggling lately, but they could be underrated buys in the long run. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Eli Lilly Eyes Obesity Access Expansion With Zepbound, Foundayo and Pipeline Bets ↗
Eli Lilly and Company (NYSE:LLY) is pursuing a broad obesity portfolio designed to address different patient needs across treatment initiation, maintenance, efficacy, tolerability and dosing... 
Via MarketBeat
News headline image
This Surprising Stock Has Been Stanley Druckenmiller's No. 1 Position for 8 Straight Quarters. Is It a No-Brainer Buy? ↗
The well-respected investor has Meta Platforms, Delta Air Lines, and Eli Lilly in his family office's portfolio. The stock isn't one of those. 
Via The Motley Fool
News headline image
Novartis Just Shook Up a Multibillion-Dollar Drug Race. What It Means for Eli Lilly Stock. ↗
Lilly may be impacted by Novartis' pelacarsen flop -- but not by much. 
Via The Motley Fool
News headline image
State Street XLV vs. iShares IXJ: Here's How These Healthcare ETFs Stack Up for Investors ↗
XLV's 0.08% expense ratio and 22.7% 1-year return outpace IXJ's global reach, but international diversification comes at a cost. 
Via The Motley Fool
Topics ETFs
News headline image
Novo Nordisk May Be Poised to Outpace Eli Lilly With This Key Catalyst ↗
Demand for Novo Nordisk's new GLP-1 pill is rising quickly, while Eli Lilly's new pill faces an important headwind. 
Via The Motley Fool
News headline image
IXJ vs XPH: Global Healthcare ETF or Pharma Focus? ↗
XPH delivered 57% returns over one year but swung 31% lower at its worst. IXJ offers steadier performance with higher income and $4.2 billion in assets for easier trading. 
Via The Motley Fool
Topics ETFs
News headline image
Could This New Opportunity Be Worth Billions for Novo Nordisk? ↗
The worst may be in the rearview mirror for the drugmaker. 
Via The Motley Fool
News headline image
Amgen Drops 10% on a Trial It Didn't Even Run ↗
AMGN stock fell after Novartis' Pelacarsen trial failed, though Amgen's own Olpasiran and Repatha differ in mechanism and results, and analysts have kept price targets largely intact. 
Via MarketBeat
News headline image
Eli Lilly Utilizes Weight-Loss Drug Profits To Fund Women's Health Initiatives: Report ↗
Eli Lilly is expanding into women's health, targeting endometriosis and pregnancy disorders by hiring experts and strategic investments. 
Via Benzinga
News headline image
These 5 ETFs Are Built for Bear Markets. History Says Now Is a Fantastic Time to Buy. ↗
During bear markets and recessions, it's good to be invested in "defensive" stocks and funds that hold up better than average. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Better Healthcare ETF: Vanguard's VHT vs. State Street's Pharmaceuticals-Focused XPH ↗
Vanguard's broader healthcare portfolio charges less and yields more, but State Street's pharma-focused fund has delivered stronger recent gains despite higher volatility. 
Via The Motley Fool
Topics ETFs
News headline image
VivoSim Labs (NASDAQ: VIVS): Predicting Drug Toxicity Before Human Clinical Trials
Via AB Newswire
News headline image
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT? ↗
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns. 
Via The Motley Fool
Topics ETFs
News headline image
Which Healthcare ETF Is the Better Buy: Fidelity's Broad FHLC or State Street's Pharma-Focused XPH? ↗
FHLC captures the whole healthcare opportunity at rock-bottom cost. XPH narrows the bet to pharmaceuticals and charges significantly more for it. 
Via The Motley Fool
Topics ETFs
News headline image
Analysts Have a $92 Target on Viking Therapeutics. Here's What Has to Go Right to Get There. ↗
This company aims to serve a market heading toward $100 billion. 
Via The Motley Fool
News headline image
CVS Health Eyes Margin Recovery, Cash Flow as 2027 Headwinds Loom ↗
CVS Health (NYSE:CVS) executives said the company is seeing improved momentum across its insurance, pharmacy, care delivery and balance-sheet priorities, while maintaining a cautious outlook on... 
Via MarketBeat
Topics Earnings
News headline image
iShares' IYH or Invesco's PBE: Which Healthcare ETF Is the Better Long-Term Buy? ↗
Broad diversification and lower costs favor iShares, but Invesco's concentrated biotech bet delivered 47% returns in one year—at the cost of steeper drawdowns. 
Via The Motley Fool
Topics ETFs
News headline image
2025 R&D Spending And Intensity Benchmarks
Via PRLog
Topics Supply Chain
News headline image
Prediction: This Is What a $5,000 Investment in Eli Lilly Will Be Worth in 2031 ↗
Hint: It's a good idea to buy the stock today. 
Via The Motley Fool
News headline image
Here’s How Much You Would Have Made Owning Eli Lilly Stock In The Last 10 Years ↗
Eli Lilly (NYSE:LLY) has outperformed the market over the past 10 years by 16.85% on an annualized basis producing an average annual return of 30.5%. Currently, Eli Lilly has a market capitalization of... 
Via Benzinga
News headline image
Is Novo Nordisk Stock Still Too Cheap for Investors to Ignore? ↗
Shares of Novo Nordisk are trading 66% below their 2024 high, but is that enough to call them cheap? Maybe. 
Via The Motley Fool
Topics Intellectual Property
News headline image
If I Were in My 20s, I'd Buy This Vanguard ETF Warren Buffett Recommended and Hold It Forever ↗
Low-cost index funds can be a ticket to prosperity for everyday investors. 
Via The Motley Fool
Topics ETFs Economy
News headline image
Healthcare ETFs Were Left Behind. JPMorgan Sees the Money Coming Back ↗
JPMorgan sees healthcare ETF flows reversing, with Eli Lilly and AbbVie among stocks that could benefit from renewed sector rotation. 
Via Benzinga
Topics ETFs
News headline image
Why Is Eli Lilly Stock Falling Tuesday? ↗
Eli Lilly (LLY) falls 2% amid a broader healthcare sell-off. Key support levels, technical breakdown, and market outlook analyzed. 
Via Benzinga
News headline image
How Novartis And Ionis' High-Profile Failure Reverberated Through Biopharma ↗
Novartis and Ionis' high-profile Lp(a) flop on Friday reverberated through biotech stocks on Tuesday. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story